Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of December 2018, specifically dated December 17, 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Forms F-3 and S-8.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quarterly results summary.
Material Changes
The filing does not detail material financial changes versus prior periods. It references a press release issued on December 17, 2018, but the content of that release is not included in the provided text, except for a note excluding a specific quote by Dr. Walid Abi-Saab from incorporation by reference.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly outlines the incorporation of the attached press release into existing registration statements.
Key Facts for Investor Verification
- Verify the actual content of the press release dated December 17, 2018 (Exhibit 99.1), as the summary text does not contain the news event details.
- Confirm the registrant name is Galapagos NV, noting a discrepancy with the "Lakefront Biotherapeutics NV" label in the request metadata.
- Check the referenced Registration Statements (File Nos. 333-211765 and various S-8 filings) for the full context of the incorporated information.
- Note that the filing explicitly excludes a quote by Dr. Walid Abi-Saab from the incorporation by reference.